NEW YORK (GenomeWeb News) – Diagnostics developer Sirius Genomics will collaborate with Vanderbilt University to study patients in a biomarker study for a drug aimed at treating severe sepsis, the company said today.
The pharmacogenomics company will work with Vanderbilt's Validating Acute Lung Injury biomarkers for Diagnosis (VALID) study to continue development of a diagnostic to assess responsiveness to recombinant human activated Protein C. The drug is sold by Eli Lilly under the trade name Xigris.
"Working with Sirius Genomics will move biomarker research in sepsis closer to the clinic and ultimately lead to improved patient care in the ICU," the VALID study's principal investigator, Lorraine Ware, said in a statement.
Financial terms of the agreement were not disclosed.